Company Filing History:
Years Active: 1997-2000
Title: Ian Wicks: Innovator in Receptor-Type Tyrosine Kinase
Introduction
Ian Wicks is a notable inventor based in Kew, Australia. He has made significant contributions to the field of biotechnology, particularly in the area of receptor-type tyrosine kinases. With a total of two patents to his name, Wicks has demonstrated his expertise and innovative spirit in scientific research.
Latest Patents
Wicks' latest patents include a groundbreaking invention related to receptor-type tyrosine kinase. This invention pertains to an isolated receptor-type tyrosine kinase characterized by its reactivity to monoclonal antibody III.A4. In its naturally occurring form, this receptor-type tyrosine kinase has an apparent molecular weight of approximately 120-150 kD in its glycosylated form, and it features the N-terminal amino acid sequence E L I P Q P. Another significant patent involves a method of screening for ligands to a receptor-type tyrosine kinase, which further showcases his innovative approach to biotechnology.
Career Highlights
Ian Wicks is currently associated with Amrad Corporation Limited, where he continues to push the boundaries of scientific research. His work has been instrumental in advancing the understanding of receptor-type tyrosine kinases and their applications in various fields.
Collaborations
Wicks has collaborated with esteemed colleagues, including Andrew W Boyd and Richard John Simpson. These partnerships have contributed to the success of his research and the development of his patents.
Conclusion
Ian Wicks is a prominent figure in the field of biotechnology, with a focus on receptor-type tyrosine kinases. His innovative patents and collaborations highlight his commitment to advancing scientific knowledge and technology.